🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: GW642444 Inhalation Powder

Found 40 matching trials

Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses

PHASE1

This study will evaluate the pharmacokinetics of FF, UMEC and VI administer...

Status

Completed

Location

GSK Investigational Site

Start Date

2013-07-15

Trial ID

NCT01894386

Treatments Being Tested

FF 400 mcg UMEC 500 mcg UMEC 250 mcg VI 100 mcg

A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 and FF in Japanese Subjects With Asthma

PHASE3

The primary purpose of the study is to assess the safety and tolerability o...

Status

Completed

Location

GSK Investigational Site

Start Date

2010-07

Trial ID

NCT01244984

Treatments Being Tested

Fluticasone Furoate/GW642444 Inhalation Powder Fluticasone Furoate Inhalation Powder

Asthma Exacerbation Study

PHASE3

This study will establish the safety as well as demonstrate benefit of the ...

Status

Completed

Location

GSK Investigational Site

Start Date

2010-02-22

Trial ID

NCT01086384

Treatments Being Tested

Fluticasone Furoate/GW642444 Fluticasone furoate

A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 in Japanese Subjects With COPD

PHASE3

The primary purpose of the study is to evaluate the safety and tolerability...

Status

Completed

Location

GSK Investigational Site

Start Date

2010-08

Trial ID

NCT01192191

Treatments Being Tested

Fluticasone Furoate/GW642444 Inhalation Powder 100/25mcg Fluticasone Furoate/GW642444 Inhalation Powder 200/25mcg

A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

This study is designed to compare the effectiveness and safety of Fluticaso...

Status

Completed

Location

GSK Investigational Site

Start Date

2012-03-13

Trial ID

NCT01551758

Treatments Being Tested

FF/VI Existing Maintenance Therapy

Phase I Study of GW642444M in Healthy Japanese Male Subjects

PHASE1

This is a randomized, double blind, placebo controlled, parallel-group, 7 d...

Status

Completed

Location

GSK Investigational Site

Start Date

2008-09-20

Trial ID

NCT00964249

Treatments Being Tested

GW642444 Placebo

Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma

PHASE3

The goal of asthma treatment is to achieve and maintain asthma control and ...

Status

Completed

Location

GSK Investigational Site

Start Date

2017-10-20

Trial ID

NCT03248128

Treatments Being Tested

FF/VI via ELLIPTA DPI FF via ELLIPTA DPI

A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

This is a multicenter, randomized, double-blind, double-dummy, parallel gro...

Status

Completed

Location

GSK Investigational Site

Start Date

2013-04-04

Trial ID

NCT01822899

Treatments Being Tested

Umeclidinium bromide/Vilanterol Placebo ACCUHALER/DISKUS Fluticasone propionate/Salmeterol Placebo NDPI

A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD

PHASE3

This is a phase III multicenter, randomized, double-blind, placebo-controll...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-03-01

Trial ID

NCT01313650

Treatments Being Tested

62.5/25mcg 62.5mcg 25mcg Placebo

Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma

PHASE3

The objective of this study is to evaluate the efficacy and safety of vilan...

Status

Completed

Location

GSK Investigational Site

Start Date

2010-09-01

Trial ID

NCT01181895

Treatments Being Tested

Vilanterol Salmeterol Inhalation Powder Placebo Inhalation Powder NDPI Placebo Inhalation Powder Diskus

Previous Next